These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7720527)

  • 1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
    Chauret N; Li C; Ducharme Y; Trimble LA; Yergey JA; Ramachandran C; Nicoll-Griffith DA
    Drug Metab Dispos; 1995 Jan; 23(1):65-71. PubMed ID: 7720527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
    Sahali-Sahly Y; Balani SK; Lin JH; Baillie TA
    Chem Res Toxicol; 1996 Sep; 9(6):1007-12. PubMed ID: 8870989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
    Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
    J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety.
    Chauret N; Nicoll-Griffith D; Friesen R; Li C; Trimble L; Dubé D; Fortin R; Girard Y; Yergey J
    Drug Metab Dispos; 1995 Dec; 23(12):1325-34. PubMed ID: 8689939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1).
    Nicoll-Griffith DA; Chauret N; Yergey JA; Trimble LA; Favreau L; Zamboni R; Grossman SJ; Drey J; Herold E
    Drug Metab Dispos; 1993; 21(5):861-7. PubMed ID: 7902249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro biotransformation of finasteride in rat hepatic microsomes. Isolation and characterization of metabolites.
    Ishii Y; Mukoyama H; Ohtawa M
    Drug Metab Dispos; 1994; 22(1):79-84. PubMed ID: 8149894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
    Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
    Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: evidence for furan bioactivation.
    Zhang KE; Naue JA; Arison B; Vyas KP
    Chem Res Toxicol; 1996 Mar; 9(2):547-54. PubMed ID: 8839061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytochrome P450 2E1 in the species-dependent biotransformation of 1,2-dichloro-1,1,2-trifluoroethane in rats and mice.
    Dekant W; Assmann M; Urban G
    Toxicol Appl Pharmacol; 1995 Dec; 135(2):200-7. PubMed ID: 8545828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
    Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
    Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of kadsurenone and 9,10-dihydrokadsurenone in rhesus monkeys and rat liver microsomes.
    Thompson KL; Chang MN; Chabala JC; Chiu SH; Eline D; Hucker HB; Sweeney BM; White SD; Arison BH; Smith JL
    Drug Metab Dispos; 1988; 16(5):737-43. PubMed ID: 2906599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450.
    Miller KK; Cai J; Ripp SL; Pierce WM; Rushmore TH; Prough RA
    Drug Metab Dispos; 2004 Mar; 32(3):305-13. PubMed ID: 14977864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of 2-amino-alpha-carboline. A food-borne heterocyclic amine mutagen and carcinogen by human and rodent liver microsomes and by human cytochrome P4501A2.
    Raza H; King RS; Squires RB; Guengerich FP; Miller DW; Freeman JP; Lang NP; Kadlubar FF
    Drug Metab Dispos; 1996 Apr; 24(4):395-400. PubMed ID: 8801053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytochrome P450 2E1 in the metabolism of 1,1,2,3,3,3-hexafluoropropyl methyl ether.
    Köster U; Speerschneider P; Kerssebaum R; Wittmann H; Dekant W
    Drug Metab Dispos; 1994; 22(5):667-72. PubMed ID: 7835215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
    Prueksaritanont T; Balani SK; Dwyer LM; Ellis JD; Kauffman LR; Varga SL; Pitzenberger SM; Theoharides AD
    Drug Metab Dispos; 1995 Jul; 23(7):688-95. PubMed ID: 7587955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.
    Kochansky CJ; Xia YQ; Wang S; Cato B; Creighton M; Vincent SH; Franklin RB; Reed JR
    Drug Metab Dispos; 2005 Dec; 33(12):1894-904. PubMed ID: 16183782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.